BIOQ
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is headquartered in Rockville, Maryland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | -0.84 | $10M | $1M |
| 2025 Q2 | -0.15 | $11M | -$2M |
| 2025 Q1 | -0.28 | $10M | — |
| 2025 Q4 | -0.11 | $12M | $6M |
| 2025 Q3 | 1.05 | $14M | $259,290 |
| 2024 Q2 | -1.36 | $11M | -$2M |
| 2024 Q1 | -0.76 | $12M | -$2M |
| 2024 Q4 | -1.31 | $12M | $4M |